Department of Hepatobiliary Surgery, Zhongshan Hospital, Xiamen University, Fujian Provincial Key Laboratory of chronic liver disease and hepatocellular carcinoma (Xiamen University Affiliated Zhongshan Hospital), Xiamen, China.
Lab Invest. 2014 Feb;94(2):182-91. doi: 10.1038/labinvest.2013.139. Epub 2013 Dec 2.
The immunosuppressive properties of hepatic stellate cells (HSCs) contribute to the occurrence and development of hepatocellular carcinoma (HCC). The accumulation of cells with immune suppressive activities, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) is a key mechanism for tumor immune evasion. However, the impact of HSCs on immune cell populations in tumor-bearing hosts is unclear. In this study, we established an orthotopic liver tumor mouse model for studying the complex tumor-host interactions in HCC. The activated HSCs promoted HCC growth not only induced tumor angiogenesis and lymphangiogenesis, but also significantly increased the suppressive immune cell population of Tregs and MDSCs in the spleen, bone marrow, and tumor tissues of the tumor-bearing mice. Murine HCC cell line H22-activated HSCs also expanded the expression of Tregs and MDSCs in vitro. In conclusion, our study suggests a novel role for HSCs in the HCC microenvironment. HSCs can promote HCC progression by enhancement of the immunosuppressive cell population. Targeting HSCs, which is a new concept in adjuvant immunotherapy, may be introduced in the near future to improve the outcome of patients with HCC.
肝星状细胞 (HSCs) 的免疫抑制特性导致了肝细胞癌 (HCC) 的发生和发展。具有免疫抑制活性的细胞的积累,如髓源抑制细胞 (MDSCs) 和调节性 T 细胞 (Tregs),是肿瘤免疫逃逸的关键机制。然而,HSCs 对肿瘤宿主中免疫细胞群体的影响尚不清楚。在本研究中,我们建立了一个原位肝癌小鼠模型,用于研究 HCC 中的复杂肿瘤-宿主相互作用。活化的 HSCs 不仅促进了 HCC 的生长,诱导了肿瘤血管生成和淋巴管生成,而且还显著增加了荷瘤小鼠脾脏、骨髓和肿瘤组织中 Tregs 和 MDSCs 的抑制性免疫细胞群体。小鼠 HCC 细胞系 H22 激活的 HSCs 也在体外扩增了 Tregs 和 MDSCs 的表达。总之,我们的研究提示了 HSCs 在 HCC 微环境中的一个新作用。HSCs 通过增强免疫抑制细胞群体促进 HCC 的进展。靶向 HSCs 可能是辅助免疫治疗的一个新概念,可能在不久的将来被引入以改善 HCC 患者的预后。
Cancer Immunol Immunother. 2019-10-23
Int J Cancer. 2020-9-15
Hepatogastroenterology. 2012
J Clin Transl Hepatol. 2025-2-28
Cancer Cell Int. 2024-8-31
J Natl Cancer Cent. 2024-1-18
Nat Rev Urol. 2024-10
Cancers (Basel). 2024-2-23
Front Pharmacol. 2024-2-1
Cancer Res. 2012-5-1
Cancer Immunol Immunother. 2011-11-27
J Immunol. 2011-4-1
Cell. 2011-3-4